SETD9

Across TCGA pan-cancer cohorts, SETD9 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of SETD9’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where SETD9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SETD9 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.

UCEC, COAD, and STAD are the cancer types where SETD9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SETD9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	III,IV	+0.587	.047	4	view →
COAD	All	All	−0.430	.002	4	view →
STAD	All	II,III,IV	+0.439	.014	3	view →
LUAD	All	All	+0.293	.003	3	view →
LIHC	Male	All	+0.396	.005	2	view →
CHOL	All	All	+0.512	.031	1	view →
READ	All	II,III,IV	−0.430	.024	1	view →
BRCA	All	All	−0.147	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

SETD9–UCEC

Open the UCEC breakdown →